Skip to main content

Table 1 Clinical characteristics of 93 patients with MPA

From: Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan

  Low BMI
(<  18.5)
(n = 22)
Normal BMI
(18.5–23.0)
(n = 53)
High BMI
(>  23)
(n = 18)
P value
Baseline characteristics
Age (years) 78 (70–81) 73 (69–78) 75 (69–78) 0.455
Male sex 15 (68.2) 27 (50.9) 8 (44.4) 0.267
BMI (kg/m2) 17.9 (17.0–18.3) 21.0 (20.0–22.1) 24.5 (23.7–26.4) < 0.001
Body weight loss > 10% within 6 months before diagnosis 12 (54.5) 24 (45.3) 4 (22.2) 0.016
lymphocyte count (/μL) 964 (792–1101) 1008 (779–1336) 1120 (935–1367) 0.221
Serum creatinine level (mg/dL) 1.6 (1.0–6.5) 1.8 (0.9–3.8) 1.3 (0.6–2.3) 0.212
Serum albumin level (mg/dL) 3.0 (2.6–3.2) 2.8 (2.4–3.3) 3.0 (2.4–3.6) 0.739
Serum IgG level (mg/dL) 1826 (1590–1967) 1818 (1602–2019) 1760 (1346–2023) 0.583
CRP level (mg/dL) 6.5 (2.3–11.1) 3.6 (1.2–9.2) 5.8 (0.3–13.2) 0.379
Diabetes mellitus 7 (31.8) 9 (17.0) 4 (22.2) 0.362
Antibody     0.122
 MPO-ANCA 22 (100) 53 (100) 17 (94.4)  
 PR3-ANCA 0 (0) 0 (0) 1 (5.6)  
 BVAS 15 (12–17) 14 (11–16) 14 (12–14) 0.591
 FFS 2 (2–3) 2 (2–3) 2 (2–3) 0.618
Organ involvement
 General 22 (100) 53 (100) 17 (94.4) 0.122
 Cutaneous 3 (13.0) 1 (1.8) 2 (10.5) 0.111
 Ear nose and throat 4 (18.2) 14 (26.4) 5 (27.8) 0.713
 Chest 6 (27.3) 20 (37.7) 5 (27.8) 0.584
  Nodules or cavities 0 (0) 0 (0) 0 (0)  
  Pleural effusion / pleurisy 0 (0) 2 (3.8) 0 (0)  
  Endobronchial involvement 0 (0) 0 (0) 0 (0)  
  Infiltrate 6 (100) 15 (75.0) 4 (80.0)  
  Alveolar hemorrhage 0 (0) 3 (5.7) 1 (5.6)  
Cardiovascular 0 (0) 0 (0) 0 (0) 0.000
Abdominal 1 (4.6) 1 (1.9) 0 (0) 0.603
Renal 19 (86.4) 42 (79.3) 14 (77.8) 0.733
 HD requirement at MPA diagnosis 5 (22.7) 1 (1.9) 2 (11.1) 0.013
Nervous system 4 (18.2) 8 (15.1) 4 (22.2) 0.779
Induction immunosuppressive therapy
 mPSL pulse therapy 11 (50.0) 25 (47.2) 8 (44.4) 0.940
 Intravenous cyclophosphamide 3 (13.6) 4 (7.6) 1 (5.6) 0.608
 Rituximab 0 (0) 3 (5.7) 2 (11.1) 0.298
Maintenance immunosuppressive therapy     0.381
 Glucocorticoidmonotherapy 16 (72.7) 38 (71.7) 13 (72.2)  
 Oralcyclophosphamide 0 (0) 1 (1.9) 1 (5.6)  
 zathioprine 5 (22.7) 12 (22.6) 2 (11.1)  
 Methotrexate 0 (0) 0 (0) 0 (0)  
 Mizoribine 1 (4.6) 0 (0) 0 (0)  
 Rituximab 0 (0) 2 (3.8) 2 (11.1)  
Outcomes
 Remission 18 (81.8) 48 (90.6) 16 (88.9) 0.562
 Relapse 7 (38.9) 17 (35.4) 6 (37.5) 0.963
 Severe infection 14 (63.6) 13 (24.5) 2 (11.1) < 0.001
 HD 8 (36.4) 11 (20.8) 4 (22.2) 0.348
 Death 7 (31.8) 13 (24.5) 2 (11.1) 0.030
 Infection 7 (100) 6 (46.2) 1 (50.0)  
 Vasculitis 0 (0) 3 (23.1) 0 (0)  
 Malignancy 0 (0) 2 (15.4) 0 (0)  
 Cardiovascular 0 (0) 0 (0) 1 (50.0)  
 Unknown 0 (0) 2 (15.4) 0 (0)  
Observation period (months) 18 (4–76) 17 (6–47) 32 (13–53) 0.828
  1. Continuous data are presented as medians (interquartile ranges), and categorical data are expressed as numbers (proportions)
  2. Abbreviations: BMI body mass index, MPO myeloperoxidase, PR3 proteinase-3 ANCA, ANCA anti-neutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, FFS Five-Factor Score, MPA microscopic polyangiitis, mPSL methylprednisolone, HD hemodialysis